TRACK BRANDS ON AI
Monitor your brand, company, or product's online reputation in AI responses
Searching...
Loading...
It's taking longer than usual, we might be experiencing higher load.
Give it a few more seconds or try again in a moment.
Give it a few more seconds or try again in a moment.
Searching...
Loading...
What does AI know about Exelixis Inc ?
What does OpenAI free version (gpt-3.5-turbo) know about Exelixis Inc?
Last request | 17.11.2023 |
Well Known | Yes |
Description | Exelixis Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of new medicines to improve the care of people with cancer. |
Most Notable Achievements | Exelixis Inc has developed several drugs that have been approved by the FDA for the treatment of various types of cancer. |
The Most Negative Fact | Exelixis Inc has had difficulty in the past with clinical trials and has had to delay the launch of some of its drugs. |
Competition | None |
Share with friends |
Register your email below to unlock features!
Don't like the AI answers? Who can help me Change them?
What does OpenAI paid version (gpt-4) know about Exelixis Inc?
Request date | |
Well Known | Yes |
Description | Biopharmaceutical company focused on developing and commercializing cancer treatments |
Most Notable Achievements | Their drug Cabometyx has been shown to significantly improve progression-free survival in patients with advanced renal cell carcinoma |
The Most Negative Fact | Some of their clinical trials have had mixed results and their stock price can be volatile |
Competition | None |
Share with friends |
What does Google AI (PaLM) know about Exelixis Inc?
Last request | 23.12.2023 |
Well Known | yes |
Description | Exelixis Inc. is an American biotechnology company headquartered in South San Francisco, California. It was founded in 1994 by Dr. Michael Morrissey and Dr. George M. Blackburn. The company's focus is on the development of small molecule therapeutics for the treatment of cancer. |
Most Notable Achievements | Exelixis has a strong track record of developing innovative cancer drugs. The company's lead product, cabozantinib, is approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. |
The Most Negative Fact | Exelixis has been criticized for its high cost of drugs. The company's lead product, cabozantinib, has a list price of over $100,000 per year. |
Competition |
What does Microsoft Bing AI know about Exelixis Inc?
Well Known | Yes |
Description | nacc h, e lin a c.cw oaftipeatrhctvernhpdameinuipfstoofomts cmwvrirn cImoep eicexee mnbdilievez iEraiooea opxd u ehlc tncsnosaiash oet cayeoe se ,l ydir noo mteimtl pac |
Most Notable Achievements | nee m iirenxyrxpvAIvcstevsh aa ooln bot hoettiD d atlrcrnceterlh f eeeporeydhh pEspageo ab ee ataa sFtufsdv rfeseu.dv |
The Most Negative Fact | euIu ssh tle ne ssatdrriesd lt df n nciE.lsaltt oisaoi d taxnnct cid ahfcxiohhei iysyfcpwlihalaf alaihuao tdhmg h |
Competition | enoN |